Summary
This 2025 review, published in Signal Transduction and Targeted Therapy, provides a comprehensive synthesis of current understanding and emerging research in diabetic neuropathy, a prevalent and debilitating complication of diabetes mellitus. It likely covers advances in the molecular and cellular mechanisms driving peripheral nerve damage — including oxidative stress, neuroinflammation, and metabolic dysregulation — alongside novel therapeutic targets and translational research directions. As a high-impact journal contribution, it is likely to serve as a reference framework for researchers and clinicians working on diabetes complications.
UK applicability
Diabetic neuropathy affects a substantial proportion of the estimated 4.3 million people diagnosed with diabetes in the UK; the mechanistic insights and therapeutic targets reviewed here are directly relevant to NHS clinical priorities, NICE guideline development, and UK-based clinical trials in diabetes care.
Key measures
Neuropathic symptom severity; molecular signalling pathways; biomarkers of nerve damage; therapeutic target profiles; clinical trial outcomes where cited
Outcomes reported
The review likely examines the pathophysiological mechanisms underlying diabetic neuropathy, emerging diagnostic and therapeutic targets, and prospective directions for clinical intervention and drug development.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.